Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Fuji
McKinsey
Teva
Citi
US Army

Generated: July 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,188,637

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,188,637
Title:Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
Abstract: The disclosure relates to granulate formulations of pirfenidone and methods of making such formulations.
Inventor(s): Mujumdar; Siddharthya Krishnachandan (Basel, CH)
Assignee: HOFFMANN-LA ROCHE INC. (Little Falls, NJ)
Application Number:15/472,222
Patent Claims: 1. A granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone, comprising: granules comprising 5-methyl-1-phenyl-2-(1H)-pyridone and a glidant; and one or more extragranular excipients comprising an extragranular glidant.

2. The formulation of claim 1, wherein the granules comprise the glidant in an amount of at least about 1% by weight based on total weight of the formulation.

3. The formulation of claim 1, wherein the granulate formulation comprises the extragranular glidant in an amount of about 0.1% to about 5% by weight, based on the total weight of the formulation.

4. The formulation of claim 1, wherein one or both of the glidant and the extragranular glidant is selected from the group consisting of silica, silicified cellulose, sodium stearate, magnesium aluminum silicate, pyrogenic silica, hydrated sodium silioaluminate, cellulose, calcium phosphate, sodium lauryl sulfate, pregelatinized starch, talc, and physical or coprocessed combinations thereof.

5. The formulation of claim 1, wherein the 5-methyl-1-phenyl-2-(1H)-pyridone is present in an amount of about 60% to about 95% by weight, based on the total weight of the formulation.

6. The formulation of claim 1, wherein the granulate formulation comprises one or more pharmaceutically acceptable excipients selected from a disintegrant, a binder, a filler, and a lubricant.

7. The formulation of claim 6, wherein, when present: the disintegrant is selected from the group consisting of agar-agar, algins, calcium carbonate, carboxymethylcellulose and salts thereof, cellulose, clays, corn starch, croscarmellose sodium, crospovidone, gums, methyl cellulose, polacrilin potassium, sodium alginate, cross-linked polyvinylpyrrolidone, sodium starch glycolate, starch, and combinations thereof; the binder is selected from the group consisting of hydroxymethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, calcium carbonate, dicalcium phosphate, carbomers, cellulose acetate phthalates, copovidone, hydroxypropyl methyl cellulose, ethylene glycol and vinyl glycol grafted copolymer, isomalt, poloxamer, polyethylene oxide, polymethacrylates, and combinations thereof; the filler is selected from the group consisting of calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium silicate, tribasic calcium sulfate, calcium carboxymethylcellulose and salts thereof, cellulose, dextrin derivatives, dextrin, dextrose, fructose, isomalt, kaolin, lactitol, lactose, magnesium carbonate, magnesium oxide, maltitol, maltodextrins, maltose, mannitol, microcrystalline cellulose, sodium bicarbonate, sodium carbonate, sorbitol, starch, sucrose, sugar, xylitol, and combinations thereof; and the lubricant is selected from the group consisting of agar, calcium stearate, ethyl oleate, ethyl laureate, glycerin, glyceryl behenate, glyceryl palmitostearate, hydrogenated vegetable oil, magnesium oxide, magnesium stearate, mannitol, poloxamer, glycols, sodium benzoate, sodium lauryl sulfate, sodium stearate, sorbitol, stearic acid, talc, zinc stearate, and combinations thereof.

8. The formulation of claim 6, wherein, when present: the binder is present in an amount of about 1% to about 10% by weight based on the total weight of the formulation; the disintegrant is present in an amount of 0% to about 10% by weight based on the total weight of the formulation; the filler is present in an amount of about 2% to about 30% by weight based on the total weight of the formulation; and the lubricant is present in an amount of about 0.05% to about 2% by weight based on the total weight of the formulation.

9. The formulation of claim 6, wherein the filler is microcrystalline cellulose, the glidant is silica, the extragranular glidant is silica, the binder is polyvinylpyrrolidone, the disintegrant is croscarmellose sodium, and the lubricant is magnesium stearate.

10. The formulation of claim 1, wherein: the granules comprise: the glidant in an amount of about 1 wt % to about 3 wt % based on the total weight of the formulation, a binder in an amount of about 1 wt % to about 10 wt % based on the total weight of the formulation, and a filler in an amount of about 2 wt % to about 30 wt %, and the one or more extragranular excipients comprise one or more of: a disintegrant in an amount of 0 wt % to about 10 wt % based on the total weight of the formulation, and a lubricant in an amount of about 0.05 wt % to about 2 wt % based on the total weight of the formulation.

11. The formulation of claim 1, wherein the granulate formulation comprises an effective amount of the glidant and the extragranular glidant to provide a flow function coefficient of the formulation of at least about 4.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Johnson and Johnson
US Department of Justice
Julphar
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.